Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Idaho
Clinical trial register · United States · industry-sponsored

Clinical Trials in Idaho, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 5290 Florida 4430 Illinois 2481 Georgia 2368 Arizona 2238
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company33 AstraZeneca15 AbbVie15 Novo Nordisk A/S14 Pfizer14
State
California5290 Florida4430 Illinois2481 Georgia2368 Arizona2238
All 51 states
Target enrolment
to

Trials with a site in Idaho

329 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
NCT07473700Hypertension, Pulmonary, Lung Diseases, Interstitial
Tectonic Operating Company, Inc.
Phase 2
25
Arizona, California, Idaho, Michigan
2026-10
Recruiting
A Study of Amicidin-β Topical Solution for Patients With Surgical or Traumatic Wound Infections
NCT07379684Surgical Wound Infection, Traumatic Wound Infection
Macro Biologics, Inc.
Phase 1
44
California, Idaho, Maryland, Missouri, Ohio
2026-09-30
By invitation
Sacroiliac Joint Fusion Intervention For Mobility, Pain Relief, and Lasting Improvement in Functional Recovery "SIMPLIFY"
NCT07849244Degenerative Sacroiliitis, Sacroiliac Disorder
OrthoFundamentals, LLC
Observational
200
Idaho
2026-09-30
Not yet open
A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy
NCT07723963Juvenile Myoclonic Epilepsy
DrugCannabidiol
Jazz Pharmaceuticals
Phase 2/3
260
Arizona, Connecticut, Florida, Georgia, Hawaii, Idaho, Louisiana, Michigan
2026-09-18
Not yet open
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
NCT07816367Migraine
DrugElismetrep
Kallyope Inc.
Phase 3
1,500
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2026-09
Not yet open
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
NCT07668336Diabetes Mellitus, Type 2
DrugsDulaglutide·Orforglipron
Eli Lilly and Company
Phase 3
170
California, Connecticut, Georgia, Idaho, Kansas, New York, Oklahoma, Pennsylvania
2026-09
Recruiting
Brexanolone Lifting Outcomes Of Moms
NCT07822321Depression, Postpartum, Postpartum Depression (PPD), Post-partum Depression, Postnatal Depression
Lipocine Inc.
Phase 3
120
Arizona, California, Colorado, Georgia, Idaho, Illinois, Louisiana, Nevada
2026-09
Not yet open
WATER IV PCa (AS Sub-study)
NCT07650448Localized Prostate Cancer
PROCEPT BioRobotics
Not applicable
333
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Maryland
2026-09
Recruiting
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT07743463Obesity, Overweight, Chronic Weight Management
DrugASC30 A1
Ascletis Pharma (China) Co., Limited
Phase 3
3,003
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho
2026-08-31
Recruiting
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT07743450Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus
DrugASC30 A1
Ascletis Pharma (China) Co., Limited
Phase 3
1,560
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho
2026-08-28
Recruiting
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
DrugOrforglipron
Eli Lilly and Company
Phase 3
2,001
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-08-26
Recruiting
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
NCT07797335Type 2 Diabetes, Cardiovascular Risk
DrugZenagamtide
Novo Nordisk A/S
Phase 3
1,778
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2026-08-24
Recruiting
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
NCT07772492Severe Alopecia Areata
DrugUpadacitinib
AbbVie
Phase 3
300
California, Florida, Idaho, Indiana, Nebraska, Ohio, Texas
2026-08-24
Recruiting
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
NCT07754461Type 2 Diabetes
DrugSurvodutide
Boehringer Ingelheim
Phase 3
600
Alabama, Arizona, Arkansas, California, Florida, Georgia, Hawaii, Idaho
2026-08-24
Not yet open
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age
NCT07742644Measles, Mumps, Rubella, Varicella (Chickenpox)
GlaxoSmithKline
Phase 3
1,860
Arkansas, California, Florida, Idaho, Illinois, Kentucky, Louisiana, Missouri
2026-08-11
Recruiting
ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection
NCT07513285Clostridium Difficile Infection Recurrence
Acurx Pharmaceuticals Inc.
Phase 2
20
California, Connecticut, Florida, Georgia, Idaho, Illinois, Massachusetts, Michigan
2026-08-06
Recruiting
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
NCT07752979Obesity, Overweight
DrugABBV-295
AbbVie
Phase 2
360
Alabama, Arizona, California, Florida, Idaho, Illinois, Kentucky, Missouri
2026-08-04
Recruiting
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
NCT07521007Atherosclerosis, Coronary Artery Disease
Beijing Inno Medicine Co., Ltd.
Phase 2
456
Alabama, California, Florida, Georgia, Idaho, Illinois, Kansas, Missouri
2026-07-31
Recruiting
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
NCT07697456Crohn's Disease, Ulcerative Colitis
DrugsTrosunilimab·ABBV-701·Risankizumab
AbbVie
Phase 2
2,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-07-31
Recruiting
Prospective Post Market Clinical Registry for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH Spring System Registry
NCT07538622BPH (Benign Prostatic Hyperplasia)
Zenflow, Inc.
Observational
300
Arizona, California, Florida, Idaho, New York, South Carolina, Texas
2026-07-29
Recruiting
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
NCT07684235Obesity, Overweight
DrugMaridebart cafraglutide
Amgen
Phase 3
3,200
Alabama, California, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois
2026-07-23
Recruiting
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
NCT07654374Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
DrugAleniglipron
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 3
1,100
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2026-07-17
Recruiting
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
NCT07654361Obesity, Overweight, Chronic Weight Management
DrugAleniglipron
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 3
3,600
Alabama, Arizona, California, Florida, Georgia, Hawaii, Idaho, Illinois
2026-07-13
Recruiting
Comparative Self-collection for Cervical Cancer Screening Pivotal Study
NCT07758140HPV, HPV - Anogenital Human Papilloma Virus Infection
Mel Mont Medical
Not applicable
260
Arizona, California, Florida, Idaho, Montana, North Carolina, Texas, Washington
2026-07-09
Recruiting
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
NCT07662213Type 2 Diabetes Mellitus
DrugsElecoglipron·Semaglutide
AstraZeneca
Phase 3
1,200
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-07-06
Recruiting
An Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of North Star Desiccated Porcine Thyroid Extract Tablets.
NCT07747103Hypothyroidism
Neuvosyn Laboratories, LLC
Phase 3
466
California, Colorado, Florida, Idaho, Massachusetts, Nevada, North Carolina, South Carolina
2026-06-30
Recruiting
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT07690371Moderate-to-Severe Atopic Dermatitis
DrugRezpegaldesleukin
Nektar Therapeutics
Phase 3
510
Arizona, Arkansas, California, Florida, Georgia, Idaho, Illinois, Kentucky
2026-06-29
Recruiting
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
NCT07357597Stomatitis
DrugDato-DXd
AstraZeneca
Phase 4
100
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho, Illinois
2026-06-24
Recruiting
Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents
NCT07660198Pneumococcal Disease
DrugsPG4·Prevnar 20
Pfizer
Phase 3
1,200
Alabama, California, Colorado, Florida, Idaho, Kentucky, Louisiana, Massachusetts
2026-06-15
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-06-11
Recruiting
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
NCT07563881Focal Seizure, Epilepsy, Focal Epilepsy
DrugRAP-219
Rapport Therapeutics Inc.
Phase 3
333
California, Florida, Georgia, Idaho, Indiana, Maryland, New Jersey, New York
2026-06-05
Recruiting
A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
NCT07489885Psoriasis
DrugD-2570
InventisBio Co., Ltd
Phase 2
75
Alabama, Arizona, California, Florida, Georgia, Idaho, Indiana, Kentucky
2026-06-03
Recruiting
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
NCT07613294Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
DrugLepodisiran
Eli Lilly and Company
Phase 3
252
California, Florida, Idaho, Massachusetts, Michigan, Nevada, Pennsylvania, Utah
2026-06-01
Recruiting
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.
NCT07629440Pneumococcal Disease
DrugsPG4·Prevnar 20
Pfizer
Phase 3
3,230
Alabama, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-05-29
Recruiting
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07599813Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic
Apollo Therapeutics Ltd
Phase 2
280
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2026-05-28
Recruiting
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
NCT07602582Alzheimer Disease, Dementia, Plaque, Amyloid
DrugDonanemab
Eli Lilly and Company
Phase 3
550
Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana, Iowa
2026-05-22
Recruiting
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414Obesity, Type 2 Diabetes
DrugsCagriSema·Semaglutide
Novo Nordisk A/S
Phase 3
2,500
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2026-05-21
Not yet open
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07400107Obesity, Overweight, Diabetes Mellitus, Type 2
DrugsNNC0487-0111·Semaglutide
Novo Nordisk A/S
Phase 3
1,000
Florida, Georgia, Idaho, Maryland, Michigan, Texas, Virginia
2026-05-20
Recruiting
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
NCT07589608Overweight, Obesity
DrugsMacupatide·Eloralintide
Eli Lilly and Company
Phase 2
400
Arizona, California, Connecticut, Florida, Idaho, Illinois, Kansas, Kentucky
2026-05-15
Recruiting
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
NCT07575399Obesity or Overweight
DrugMaridebart cafraglutide
Amgen
Phase 3
300
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Louisiana
2026-05-11
Recruiting
A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants
NCT07573462Pneumococcal Disease
DrugsPG4·Prevnar 20
Pfizer
Phase 3
2,400
Florida, Georgia, Idaho, Illinois, Kentucky, Louisiana, Massachusetts, New York
2026-05-04
Recruiting
Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes
NCT07521475Type 2 Diabetes Mellitus
Insulet Corporation
Not applicable
350
California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana, Massachusetts
2026-04-30
Recruiting
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
NCT07446322Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer
DrugsPelareorep·Folfiri·Avastin·Bevacizumab
Oncolytics Biotech
Phase 2
60
Alabama, California, Florida, Georgia, Idaho, Illinois, Indiana, Michigan
2026-04-30
Recruiting
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
NCT07486960Psoriatic Arthritis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
140
Arizona, California, Florida, Idaho, Maryland, Missouri, Nebraska, New York
2026-04-20
Recruiting
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
NCT07415954Diabetes Mellitus, Type 2
DrugsNNC0662-0419·Semaglutide
Novo Nordisk A/S
Phase 2
270
California, Florida, Idaho, Illinois, Massachusetts, Missouri, North Carolina, Ohio
2026-04-17
Recruiting
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
NCT07481630Obesity, Knee Osteoarthritis (OA)
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
400
Arizona, California, Connecticut, Florida, Georgia, Idaho, Massachusetts, Nevada
2026-04-13
Recruiting
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
NCT07519395Irritable Bowel Syndrome
DrugCamlipixant
GlaxoSmithKline
Phase 2
420
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-04-08
Recruiting
Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix
NCT07543757Prostate Cancer Detection
Sequenom, Inc.
Observational
500
California, Idaho, Kentucky, Maryland, New York, South Carolina
2026-04-03
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois, Indiana
2026-03-26
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058Obesity or Overweight, Type 2 Diabetes Mellitus
Hoffmann-La Roche
Phase 3
1,600
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Idaho, Louisiana
2026-03-23
Active, closed
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
NCT07496450Influenza
ModernaTX, Inc.
Phase 3
4,050
California, Georgia, Idaho, Maryland, Nebraska, Ohio, Rhode Island, South Carolina
2026-03-23
Recruiting
Post Approval Effectiveness and Durability Evaluation of the Altaviva™ Tibial Device
NCT07456865Urge Urinary Incontinence
MedtronicNeuro
Not applicable
256
Alabama, Idaho, Missouri, North Carolina, Ohio, Pennsylvania, South Carolina, South Dakota
2026-03-17
Recruiting
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
NCT07404865Primary Sjogren's Disease
DrugTelitacicept
Vor Biopharma
Phase 3
250
Arizona, California, Colorado, Florida, Idaho, Illinois, Louisiana, Maryland
2026-02-26
Recruiting
REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool
NCT07280065PTSD - Post Traumatic Stress Disorder
Senseye, Inc.
Phase 3
1,900
Colorado, Georgia, Idaho, Massachusetts, South Carolina
2026-02-23
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190Overweight, Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
900
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-02-10
Recruiting
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
NCT07353931Osteoarthritis, Overweight or Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
900
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-02-09
Recruiting
A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout
NCT07388498Uncontrolled Gout
DrugMethotrexate
Amgen
Phase 3
270
Alabama, Alaska, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-02-09
Active, closed
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
NCT07228117Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Medtronic MiniMed, Inc.
Not applicable
389
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois
2026-02-02
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695Non-small Cell Lung Cancer
DrugsZongertinib·Atezolizumab·Durvalumab·Nivolumab
Boehringer Ingelheim
Phase 3
400
California, District of Columbia, Florida, Georgia, Idaho, Illinois, Massachusetts, Nevada
2026-01-16
Recruiting
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
NCT07266402Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
240
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Kentucky
2026-01-15
Recruiting
A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis
NCT07355062CKD, Metabolic Acidosis
Renibus Therapeutics, Inc.
Phase 3
150
California, Colorado, Delaware, Florida, Georgia, Idaho, Illinois, Indiana
2026-01-13
Recruiting
A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
NCT07382167Chronic Idiopathic Constipation (CIC)
DrugTenapanor
Ardelyx
Phase 3
692
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2026-01-13
Recruiting
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT07253285Overweight, Obesity
DrugsCagrilintide·Semaglutide
Novo Nordisk A/S
Phase 3
460
California, Florida, Georgia, Idaho, Indiana, Kansas, Louisiana, Maryland
2026-01-08
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion
DrugsNavlimetostat·Nab-paclitaxel·Pemetrexed·Paclitaxel
Bristol-Myers Squibb
Phase 2/3
590
Alaska, Arizona, Arkansas, California, Delaware, Florida, Idaho, Illinois
2026-01-02
Recruiting
A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease
NCT07254806Degenerative Disc Disease
DiscGenics, Inc.
Phase 3
162
Alabama, Arizona, California, District of Columbia, Florida, Idaho, Indiana, Kentucky
2025-12-23
Recruiting
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
NCT07219407Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure
DrugRAP-219
Rapport Therapeutics Inc.
Phase 2
30
Idaho, Minnesota, New York, Ohio, Pennsylvania, Tennessee, Texas
2025-12-15
Recruiting
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
NCT07221851Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
Ascendis Pharma A/S
Phase 3
186
California, Colorado, Delaware, District of Columbia, Florida, Georgia, Idaho, Louisiana
2025-12-12
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Idaho
2025-12-12
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site
DrugsPF-08634404·Avastin·Bevacizumab
Pfizer
Phase 3
800
Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2025-12-11
Active, closed
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
NCT07219602Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)
DrugsEzetimibe FDC·Obicetrapib
NewAmsterdam Pharma
Phase 3
300
Arizona, California, Florida, Idaho, Illinois, Kentucky, Maine, Maryland
2025-12-11
Recruiting
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
NCT07285213Clostridioides Difficile Infection
AstraZeneca
Phase 2
230
Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois, Kentucky
2025-12-10
Recruiting
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453Plaque Psoriasis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
366
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Indiana
2025-12-03
Recruiting
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
NCT06807281Atopic Dermatitis
DrugAbrocitinib
Pfizer
Phase 3
500
Alabama, Arkansas, California, Florida, Idaho, Indiana, Missouri, South Carolina
2025-12-02
Recruiting
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
NCT07144852Actinic Keratosis
Sun Pharmaceutical Industries, Inc.
Phase 3
260
Arizona, California, Colorado, Florida, Idaho, Illinois, Indiana, Minnesota
2025-11-29
Recruiting
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
NCT07296484Type 2 Diabetes, Cortisol Excess
DrugClofutriben
Sparrow Pharmaceuticals
Phase 2
1,500
Arizona, California, Florida, Georgia, Idaho, Illinois, Iowa, Kansas
2025-11-29
Recruiting
Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women
NCT07209397Overactive Bladder, Overactive Bladder (OAB), Urge Urinary Incontinence, Mixed Urinary Incontinence (Urge-Predominant)
InMode MD Ltd.
Not applicable
202
California, District of Columbia, Idaho, Illinois, Kansas, Massachusetts, Nebraska, Nevada
2025-11-25
Active, closed
Efficacy and Safety of NVX-CoV2705
NCT07086222COVID-19, Sars-CoV-2 Infection
Novavax
Phase 4
6,500
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-11-20
Active, closed
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome
NCT07211685Alport Syndrome
Bayer
Phase 2
60
Alabama, Florida, Georgia, Idaho, Massachusetts, Texas
2025-11-19
Active, closed
A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
NCT07187115Atrial Fibrillation (AF), Persistant Atrial Fibrillation
Boston Scientific Corporation
Not applicable
699
Arkansas, California, Georgia, Idaho, New York, Ohio, Pennsylvania, Texas
2025-11-07
Active, closed
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
NCT06851559Eosinophilic Esophagitis
DrugVonoprazan
Phathom Pharmaceuticals, Inc.
Phase 2
95
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois
2025-10-30
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
NCT06701656Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
DrugBevacizumab
PPD Development, LP
Phase 2
200
Alabama, California, Colorado, District of Columbia, Florida, Idaho, Illinois, Massachusetts
2025-10-28
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin
Hoffmann-La Roche
Phase 3
600
Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-24
Active, closed
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121Pancreatic Ductal Adenocarcinoma
DrugsNavlimetostat·Abraxane·Nab-paclitaxel·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
470
Arizona, Arkansas, California, Florida, Georgia, Idaho, Illinois, Kansas
2025-10-23
Recruiting
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
NCT07069738Heart Failure - NYHA II - IV
Boston Scientific Corporation
Not applicable
850
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho
2025-10-22
Recruiting
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
NCT07177339Pulmonary Disease, Chronic Obstructive
DrugDepemokimab
GlaxoSmithKline
Phase 3
1,196
California, Colorado, Florida, Georgia, Idaho, Kentucky, Louisiana, Maine
2025-10-20
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07184996Ulcerative Colitis
DrugDuvakitug
Sanofi
Phase 3
980
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-08
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931Crohn's Disease
DrugDuvakitug
Sanofi
Phase 3
980
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-01
Recruiting
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT07204275Primary Membranous Nephropathy
DrugsPovetacicept·Tacrolimus
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2025-09-30
Active, closed
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
NCT06946797Non-Small Cell Lung Cancer
DrugsNivolumab and rHuPH20·Yervoy·Ipilimumab·Pemetrexed
Bristol-Myers Squibb
Phase 2
76
Alaska, California, Idaho, Ohio, Pennsylvania
2025-09-19
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-09-02
Recruiting
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
NCT07160244Healthy
DrugPrevnar 20
Pfizer
Phase 3
6,000
Alabama, Arizona, California, Colorado, Florida, Idaho, Louisiana, Maryland
2025-08-25
Recruiting
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
NCT07154706Non-small Cell Lung Cancer (NSCLC)
DrugTaletrectinib
Nuvation Bio Inc.
Phase 3
180
California, District of Columbia, Florida, Idaho, Louisiana, Massachusetts, Minnesota, New York
2025-08-21
Active, closed
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
NCT07076199Diabetes Mellitus, Type 1
DrugsInsulin aspart·Insulin glargine·Insulin icodec
Novo Nordisk A/S
Phase 3
877
Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2025-08-11
Recruiting
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
NCT07088068Type 1 Diabetes Mellitus
DrugsTzield·Teplizumab
Sanofi
Phase 3
723
Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho, Kentucky
2025-08-06
Recruiting
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
NCT07133308Alopecia Areata
DrugDeuruxolitinib
Sun Pharmaceutical Industries, Inc.
Phase 3
355
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2025-08-05
Recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433Atherosclerotic Cardiovascular Disease, Overweight, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
12,800
Alabama, Arizona, California, Delaware, Florida, Georgia, Idaho, Illinois
2025-07-25
Active, closed
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
NCT07146022Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia
DrugVDPHL01
Veradermics, Inc.
Phase 3
552
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2025-07-25
Recruiting
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
NCT06807268Eczema
DrugAbrocitinib
Pfizer
Phase 3
150
Alabama, Arkansas, California, Florida, Idaho, Indiana, Missouri, South Carolina
2025-07-24
Recruiting
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma
DrugsBevacizumab biosimilar·Calderasib·Mvasi·Erbitux
Merck Sharp & Dohme LLC
Phase 3
477
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Iowa
2025-07-16
Recruiting
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827Kidney Disease
DrugMezagitamab
Takeda
Phase 3
347
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Louisiana
2025-07-15
Recruiting
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
NCT07013474COVID-19 Infection
DrugsIbuzatrelvir·Veklury·Remdesivir
Pfizer
Phase 3
300
California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois, Maryland
2025-07-14
Recruiting
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099Crohn's Disease, Obesity or Overweight
DrugsMirikizumab·Tirzepatide
Eli Lilly and Company
Phase 3
290
Alabama, California, Florida, Idaho, Illinois, Indiana, Kentucky, Louisiana
2025-06-26
Recruiting
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086Ulcerative Colitis, Obesity or Overweight
DrugsMirikizumab·Tirzepatide
Eli Lilly and Company
Phase 3
350
Alabama, California, Florida, Idaho, Illinois, Indiana, Kentucky, Louisiana
2025-06-26
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2025-06-25
Recruiting
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
NCT06961214Pulmonary Disease, Chronic Obstructive
DrugDepemokimab
GlaxoSmithKline
Phase 3
961
Alabama, Colorado, Florida, Georgia, Idaho, Illinois, Louisiana, Maine
2025-06-23
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
NCT06701682Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
DrugVilobelimab
PPD Development, LP
Phase 2
200
Alabama, California, Colorado, District of Columbia, Florida, Idaho, Illinois, Massachusetts
2025-06-21
Active, closed
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
NCT06832618Atopic Dermatitis
DrugRuxolitinib
Incyte Corporation
Phase 3
159
Alabama, Arizona, Colorado, Florida, Georgia, Idaho, Illinois, Maryland
2025-06-17
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
NCT06701669Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
DrugParidiprubart
PPD Development, LP
Phase 2
200
Alabama, California, Colorado, District of Columbia, Florida, Idaho, Illinois, Massachusetts
2025-06-10
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
NCT06703073Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
DrugsParidiprubart·Vilobelimab·Bevacizumab
PPD Development, LP
Phase 2
600
Alabama, California, Colorado, District of Columbia, Florida, Idaho, Illinois, Massachusetts
2025-06-10
Recruiting
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT06902558Autosomal Dominant Polycystic Kidney Disease
Calico Life Sciences LLC
Phase 2
240
Alabama, California, Connecticut, Florida, Georgia, Idaho, Illinois, Iowa
2025-06-09
Recruiting
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
NCT07028489Non Small Cell Lung Cancer
N-Power Medicine
Observational
130
California, Delaware, Idaho, Illinois, New Mexico, Pennsylvania, Texas
2025-06-05
Active, closed
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
NCT06735534Persistent Atrial Fibrillation
Boston Scientific Corporation
Not applicable
376
Alabama, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2025-06-03
Active, closed
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
NCT07011706Atopic Dermatitis, Atopic, Dermatitis, AD
Aclaris Therapeutics, Inc.
Phase 2
110
Arizona, Arkansas, California, Florida, Georgia, Idaho, Indiana, Kentucky
2025-05-30
Active, closed
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
NCT06931405Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Blueprint Medicines Corporation
Phase 2
105
Alabama, Arkansas, California, Florida, Idaho, Illinois, Indiana, Kentucky
2025-05-28
Recruiting
Clinical Study of a Vaginal Cooling Device for the Treatment of Vulvovaginal Candidiasis (VVC)
NCT06983041Vulvovaginal Candidiasis (VVC), Yeast Vaginitis
Coologics, Inc
Not applicable
55
Florida, Georgia, Idaho, Illinois, North Carolina, Tennessee, Texas
2025-05-22
Active, closed
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
NCT06966479Severe Asthma
DrugVerekitug
Upstream Bio Inc.
Phase 2
396
California, Florida, Idaho, Maryland, Michigan, Nevada, New York, Ohio
2025-05-21
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
600
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-19
Active, closed
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459Obesity, Overweight
DrugOrforglipron
Eli Lilly and Company
Phase 3
800
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-15
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792Obesity, Overweight, Type 2 Diabetes
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,400
Arizona, California, Florida, Georgia, Idaho, Louisiana, Maryland, Michigan
2025-05-15
Recruiting
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
NCT06783309Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus
COUR Pharmaceutical Development Company, Inc.
Phase 1/2
72
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2025-05-12
By invitation
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study
NCT06914908Chronic Rhinosinusitis With Nasal Polyps
DrugsLunsekimig·Mometasone furoate
Sanofi
Phase 2
71
California, Idaho, Oklahoma, Texas, Virginia
2025-05-12
Active, closed
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895Type 1 Diabetes, Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
905
California, Colorado, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa
2025-04-25
Active, closed
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
NCT06881836Alzheimer Disease
DrugONO-2020
Ono Pharmaceutical Co., Ltd.
Phase 2
260
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Kansas
2025-04-24
Recruiting
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
NCT06855160Chickenpox
DrugsMarketed varicella vaccine·Hepatitis A vaccine·MMR vaccine·PCV (pneumococcal conjugate vaccine) 13
GlaxoSmithKline
Phase 3
911
Arizona, California, Florida, Idaho, Ohio, Texas, Virginia
2025-04-17
Recruiting
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
NCT06866405RSV Infection
DrugRSVpreF
Pfizer
Phase 3
550
Alabama, Arizona, California, Colorado, Florida, Idaho, Iowa, Kansas
2025-04-16
Recruiting
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475Type 2 Diabetes
Eli Lilly and Company
Phase 2
200
Arizona, California, Florida, Georgia, Idaho, Indiana, New Jersey, New York
2025-03-28
Recruiting
Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
NCT06827262Chronic Low-back Pain, Vertebrogenic Pain Syndrome
Boston Scientific Corporation
Observational
1,500
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Idaho, Illinois
2025-03-26
Recruiting
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
NCT06932263Asthma
DrugTozorakimab
AstraZeneca
Phase 2
540
California, Delaware, Florida, Idaho, Indiana, Iowa, Kansas, Kentucky
2025-03-26
Active, closed
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
NCT06857955Hypertension
DrugQCZ484
Novartis Pharmaceuticals
Phase 2
396
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-03-26
Active, closed
Evaluating SUI-100™, A Non-Invasive Device for the Treatment of Stress Urinary Incontinence
NCT06862648Stress Urinary Incontinence (SUI)
Acoustic Wave Cell Therapy, Inc.
Not applicable
130
Arizona, Florida, Idaho, Kansas, Montana, Nevada, Ohio, Texas
2025-03-25
Recruiting
Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis
NCT06911424Bacterial Conjunctivitis
Baxis Pharmaceuticals, Inc.
Phase 3
400
Arkansas, California, Florida, Georgia, Idaho, Illinois, Maryland, Nevada
2025-03-21
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
NCT06883305Chronic Obstructive Pulmonary Disease (COPD)
DrugTezepelumab
AstraZeneca
Phase 3
990
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-03-18
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878Moderately to Severely Active Crohns Disease
DrugAfimkibart
Hoffmann-La Roche
Phase 3
600
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2025-03-17
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354Triple Negative Breast Neoplasms
DrugsAbraxane·Sacituzumab tirumotecan·Paraplatin·Taxol
Merck Sharp & Dohme LLC
Phase 3
1,000
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Idaho
2025-03-16
Active, closed
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858839Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
3,853
Alabama, Arizona, California, Connecticut, Florida, Georgia, Hawaii, Idaho
2025-03-12
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466Menstrual Migraine
DrugRimegepant
Pfizer
Phase 3
723
Arizona, California, Florida, Georgia, Idaho, Indiana, Michigan, Missouri
2025-03-11
Recruiting
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
NCT06806033Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
DrugsGlofitamab·Obinutuzumab·Oxaliplatin·Gemcitabine
Hoffmann-La Roche
Phase 2
130
Alaska, California, Colorado, Florida, Idaho, Illinois, Iowa, Kentucky
2025-03-05
Recruiting
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
NCT06797518Glomerulonephritis, IGA, Immunoglobulin A Nephropathy
DrugIptacopan
Novartis Pharmaceuticals
Phase 2
20
Alabama, California, Florida, Georgia, Idaho, Nevada, Ohio, Texas
2025-02-21
Active, closed
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT06824194Pneumococcal Immunization
DrugsHavrix·Vaqta·M-M-R II vaccine·Prevnar 20 vaccine
Sanofi
Phase 3
2,360
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho
2025-02-18
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347Chronic Rhinosinusitis With Nasal Polyps
DrugsItepekimab·Mometasone furoate
Sanofi
Phase 3
231
California, Florida, Georgia, Idaho, Illinois, Indiana, Missouri, New York
2025-02-12
By invitation
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
NCT06908226Developmental and Epileptic Encephalopathy
DrugBexicaserin
Longboard Pharmaceuticals
Phase 3
324
Arkansas, California, Colorado, Florida, Idaho, Maryland, Massachusetts, Minnesota
2025-02-12
Recruiting
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
NCT06624670Pyoderma Gangrenosum
DrugsSpesolimab·Prednisolone·Prednisone
LEO Pharma
Phase 3
90
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-02-05
Active, closed
WATER IV Prostate Cancer
NCT06651632Localized Prostate Cancer
PROCEPT BioRobotics
Not applicable
280
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Maryland
2025-02-03
Recruiting
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
NCT06548360NonSegmental Vitiligo
DrugRuxolitinib
Incyte Corporation
Phase 3
180
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2025-01-24
Active, closed
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
NCT06684847Primary Sjogrens Disease
DrugEfgartigimod PH20
argenx
Phase 3
631
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2025-01-15
Active, closed
Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential
NCT06672016Female Contraception
Mylan Pharmaceuticals Inc
Phase 3
1,630
Alabama, Arizona, California, Florida, Georgia, Idaho, Kansas, Kentucky
2025-01-13
Recruiting
PerQdisc Traditional Feasibility Trial.
NCT06860867Discogenic Low Back Pain
Spinal Stabilization Technologies
Not applicable
5
Arizona, Idaho, Indiana, Louisiana, Oklahoma
2025-01-10
Recruiting
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
NCT06740630Chickenpox
DrugsHepatitis A vaccine·MMR vaccine·PCV (pneumococcal conjugate vaccine) 13·PCV 20
GlaxoSmithKline
Phase 3
1,840
Alabama, Arkansas, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-01-10
Active, closed
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
NCT06679985Hepatocellular Carcinoma
DrugsToripalimab·Bevacizumab
Coherus Oncology, Inc.
Phase 2
72
Arizona, California, Florida, Georgia, Idaho, Kansas, Kentucky, Mississippi
2024-12-20
Recruiting
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
NCT06775379Major Depressive Disorder
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
450
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2024-12-20
Active, closed
A Study of Barzolvolimab in Patients With Atopic Dermatitis
NCT06727552Atopic Dermatitis
DrugBarzolvolimab
Celldex Therapeutics
Phase 2
131
Alabama, California, Florida, Georgia, Idaho, Illinois, Kentucky, Michigan
2024-12-18
Active, closed
Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
NCT06696443Diabetic Peripheral Neuropathic Pain
DrugSuzetrigine
Vertex Pharmaceuticals Incorporated
Phase 3
455
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2024-12-18
Active, closed
Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
NCT06736041Pneumococcal Immunization
DrugsM-M-R II vaccine·Prevnar 20 vaccine·RotaTeq·PCV21 vaccine
Sanofi Pasteur, a Sanofi Company
Phase 3
1,714
Arizona, Arkansas, California, District of Columbia, Florida, Idaho, Kansas, Maryland
2024-12-18
Recruiting
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
NCT06664619Asthma
Teva Branded Pharmaceutical Products R&D LLC
Phase 3
724
Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2024-12-12
Recruiting
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
NCT06679140COVID-19 SARS-CoV-2 Infection
DrugIbuzatrelvir
Pfizer
Phase 3
2,330
Alabama, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2024-12-08
Recruiting
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
NCT06667700Coronavirus Disease (COVID-19)
DrugMolnupiravir
Merck Sharp & Dohme LLC
Phase 3
3,082
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2024-12-02
Active, closed
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
NCT06720038Pneumococcal Vaccines
DrugPrevnar 20
Vaxcyte, Inc.
Phase 2
900
Arkansas, California, Colorado, Florida, Idaho, Kentucky, Louisiana, Nebraska
2024-11-25
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel
AstraZeneca
Phase 3
1,160
Arizona, Arkansas, California, Connecticut, Delaware, Florida, Georgia, Idaho
2024-11-18
Active, closed
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older
NCT06686654Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
DrugHMPV vaccine
Sanofi Pasteur, a Sanofi Company
Phase 1/2
1,530
Arizona, California, Colorado, District of Columbia, Florida, Idaho, Kansas, Maryland
2024-11-11
Active, closed
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
NCT06719141Developmental and Epileptic Encephalopathy
DrugBexicaserin
Longboard Pharmaceuticals
Phase 3
367
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois
2024-11-11
Active, closed
A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
NCT06614192Metastatic Colorectal Cancer
DrugTelisotuzumab Adizutecan
AbbVie
Phase 2
74
California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana
2024-11-08
Active, closed
Efficacy and Safety of VDPHL01 in Males With AGA
NCT06724614Androgenetic Alopecia, AGA, Male Pattern Baldness
DrugVDPHL01
Veradermics, Inc.
Phase 2/3
480
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2024-11-06
Active, closed
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
NCT06602232Alopecia Areata, Vitiligo
DrugDibotatug
Dren Bio
Phase 1
81
California, Florida, Georgia, Idaho, Indiana, Massachusetts, Michigan, Pennsylvania
2024-10-30
Active, closed
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153Alzheimer's Disease
DrugRemternetug
Eli Lilly and Company
Phase 3
1,400
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2024-10-24
Recruiting
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
NCT06382155Idiopathic Short Stature
DrugsHuman Growth Hormone·Vosoritide
BioMarin Pharmaceutical
Phase 2
100
California, District of Columbia, Florida, Georgia, Idaho, Iowa, Kentucky, Louisiana
2024-10-21
Recruiting
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT06623422Carcinoma, Non-Small-Cell Lung
DrugsIntismeran autogene·Paraplatin·Taxol·Pemetrexed
Merck Sharp & Dohme LLC
Phase 3
680
Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois, Indiana
2024-10-21
Recruiting
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
NCT06619860Diabetic Peripheral Neuropathic Pain
DrugPregabalin
Vertex Pharmaceuticals Incorporated
Phase 2
300
Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Michigan
2024-10-18
Active, closed
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
NCT06598462Eosinophilic Esophagitis (EoE)
DrugSolrikitug
Uniquity One (UNI)
Phase 2
184
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois
2024-10-16
Active, closed
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
NCT06453213Focal Onset Seizure
DrugCenobamate
SK Life Science, Inc.
Phase 4
49
Arizona, Arkansas, California, Connecticut, Florida, Idaho, Kentucky, Louisiana
2024-10-14
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386Non-small Cell Lung Cancer
DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin
Bristol-Myers Squibb
Phase 3
1,000
Alabama, Arizona, California, Colorado, Florida, Idaho, Illinois, Kansas
2024-10-07
Recruiting
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
NCT06628908Diabetic Peripheral Neuropathic Pain
DrugsSuzetrigine·Pregabalin
Vertex Pharmaceuticals Incorporated
Phase 3
1,100
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2024-10-01
Active, closed
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
NCT06592794Acute Gastroenteritis, Norovirus Acute Gastroenteritis
DrugMRNA-1403
ModernaTX, Inc.
Phase 3
37,864
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2024-09-24
Active, closed
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
NCT06571383Obesity
DrugSemaglutide
Novo Nordisk A/S
Phase 4
500
California, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Louisiana
2024-09-17
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986Moderately to Severely Active Ulcerative Colitis
DrugAfimkibart
Hoffmann-La Roche
Phase 3
400
Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2024-09-17
Recruiting
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
NCT06246916Melanoma
DrugsFianlimab·Relatlimab·Cemiplimab·Nivolumab
Regeneron Pharmaceuticals
Phase 3
560
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2024-09-09
Recruiting
RevCore for In Stent Thrombosis
NCT06394739In-stent Thrombosis
Inari Medical
Observational
100
Connecticut, District of Columbia, Idaho, Maryland, New York, North Carolina, Ohio, Pennsylvania
2024-09-09
Active, closed
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076Plaque Psoriasis
DrugZasocitinib
Takeda
Phase 3
2,099
Alabama, Arizona, Arkansas, California, Florida, Georgia, Idaho, Illinois
2024-09-04
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542Crohn's Disease
DrugsABBV-8736·Trosunilimab·Lutikizumab·Risankizumab
AbbVie
Phase 2
590
Alabama, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois
2024-09-04
Active, closed
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
NCT06616974Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Tectonic Therapeutic
Phase 2
191
Arizona, California, Colorado, Florida, Georgia, Idaho, Kentucky, Maryland
2024-09-04
Active, closed
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824Kidney Disease, Chronic
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
11,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2024-08-30
Active, closed
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142Immunoglobulin A Nephropathy
DrugPovetacicept
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Idaho
2024-08-30
Active, closed
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
NCT06557772Coeliac Disease, Celiac Disease
DrugAmlitelimab
Sanofi
Phase 2
229
Arizona, California, Colorado, Florida, Idaho, Kansas, Massachusetts, Michigan
2024-08-29
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
DrugAZD7798
AstraZeneca
Phase 2
120
Arizona, California, Florida, Idaho, Kansas, Michigan, Missouri, North Carolina
2024-08-28
Active, closed
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
NCT06572228Asthma
DrugsICS/LABA·Dupilumab
Regeneron Pharmaceuticals
Phase 4
120
California, Colorado, Florida, Idaho, Illinois, Kansas, Kentucky, Maine
2024-08-26
Active, closed
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498Multiple Myeloma
DrugsAnitocabtagene Autoleucel·Carfilzomib·Pomalidomide·Bortezomib
Kite, A Gilead Company
Phase 3
452
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2024-08-23
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06461897Atopic Dermatitis
DrugsUpadacitinib·Dupilumab
AbbVie
Phase 3
675
Arkansas, California, Florida, Georgia, Idaho, Illinois, Indiana, Kentucky
2024-08-19
Active, closed
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
NCT06496620COPD
DrugSolrikitug
Uniquity One (UNI)
Phase 2
182
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2024-08-14
Recruiting
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357Biliary Tract Cancer
DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine
AstraZeneca
Phase 3
620
Arizona, California, District of Columbia, Florida, Georgia, Idaho, Illinois, Maryland
2024-08-12
Recruiting
A Study to Assess Growth in Children With Idiopathic Short Stature
NCT06309979Idiopathic Short Stature
BioMarin Pharmaceutical
Observational
300
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Idaho, Kentucky
2024-08-08
Active, closed
A Study to Evaluate Solriktug in Adult Participants With Asthma
NCT06496607Asthma
Uniquity One (UNI)
Phase 2
145
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2024-07-26
Active, closed
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants
NCT06524414Pneumococcal Disease
DrugsPG4·Prevnar 20
Pfizer
Phase 2
605
Arkansas, California, District of Columbia, Florida, Idaho, Iowa, Kansas, Kentucky
2024-07-25
Active, closed
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
976
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2024-07-19
Active, closed
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT06445023Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
963
Alabama, California, Colorado, Florida, Idaho, Illinois, Indiana, Kentucky
2024-07-11
By invitation
Continuation Protocol for Obstructive Sleep Apnea (OSA)
NCT06566820OSA
Apnimed
Phase 3
1,280
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2024-07-03
Active, closed
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228Hidradenitis Suppurativa
DrugLutikizumab
AbbVie
Phase 3
1,400
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2024-06-27
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288Heart Failure
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
6,712
Alabama, California, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana
2024-06-17
Recruiting
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
NCT06389136Atopic Dermatitis
DrugsUpadacitinib·Dupilumab
AbbVie
Phase 3
200
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2024-06-14
Active, closed
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
NCT06334133Diabetes Mellitus, Type 1
DrugCadisegliatin
vTv Therapeutics
Phase 3
150
Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho, Indiana
2024-06-14
Recruiting
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277Obesity, Weight Gain
DrugTirzepatide
Eli Lilly and Company
Phase 3
300
California, Delaware, Idaho, Illinois, Indiana, New York, Texas, Utah
2024-06-03
Active, closed
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT05963074Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma
DrugsVenclyxto·Ibrutinib·Venclexta·Venetoclax
Janssen Research & Development, LLC
Phase 2
333
California, Colorado, Florida, Idaho, Illinois, Iowa, Minnesota, Missouri
2024-05-30
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2024-05-20
Recruiting
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
DrugLebrikizumab
Eli Lilly and Company
Phase 3
510
Alabama, Arizona, California, Colorado, Florida, Idaho, Illinois, Kansas
2024-04-29
Recruiting
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
NCT06345339Hypothyroidism
DrugLevothyroxine
AbbVie
Phase 2/3
2,800
Alabama, California, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois
2024-04-26
Active, closed
A Study of Barzolvolimab in Patients With Prurigo Nodularis
NCT06366750Prurigo Nodularis
DrugBarzolvolimab
Celldex Therapeutics
Phase 2
140
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2024-04-12
Active, closed
Study of JK07 in Patients With Chronic Heart Failure
NCT06369298Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Salubris Biotherapeutics Inc
Phase 2
282
Alabama, Arizona, Arkansas, California, Florida, Georgia, Idaho, Illinois
2024-03-28
Active, closed
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
NCT06297603Type 2 Diabetes
DrugRetatrutide
Eli Lilly and Company
Phase 3
320
Alabama, Arizona, California, Florida, Georgia, Idaho, Kansas, Montana
2024-03-15
Active, closed
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
NCT06299098Obesity
DrugsGaretosmab·Wegovy·Semaglutide
Regeneron Pharmaceuticals
Phase 2
1,005
Alabama, Arizona, California, Florida, Georgia, Hawaii, Idaho, Illinois
2024-03-13
Recruiting
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
NCT06112418Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Cleerly, Inc.
Not applicable
7,500
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2024-03-06
Active, closed
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer
DrugsSonesitatug Vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib
AstraZeneca
Phase 3
594
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Idaho, Kentucky
2024-03-04
Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966COPD (Chronic Obstructive Pulmonary Disease)
AstraZeneca
Phase 3
5,250
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2024-02-21
Active, closed
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
NCT06260722Diabetes Mellitus, Type 2
DrugsRetatrutide·Semaglutide
Eli Lilly and Company
Phase 3
1,250
Alabama, California, Colorado, Florida, Georgia, Hawaii, Idaho, Indiana
2024-02-21
Active, closed
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744Follicular Lymphoma (FL)
DrugsEpcoritamab·Bendamustine·Obinutuzumab·Vincristine
Genmab
Phase 3
1,095
California, Colorado, Delaware, Florida, Idaho, Illinois, Indiana, Iowa
2024-02-05
Active, closed
ZILRETTA in Subjects With Shoulder Osteoarthritis
NCT06269705Glenohumeral Osteoarthritis
Pacira Pharmaceuticals, Inc
Phase 3
150
Alabama, Arizona, California, District of Columbia, Florida, Idaho, Kansas, Louisiana
2024-02-05
Active, closed
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150Multiple Myeloma
DrugsElotuzumab·Talquetamab·Velcade·Teclistamab
Janssen Research & Development, LLC
Phase 3
838
California, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Iowa
2024-01-22
Recruiting
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638Hypertension, Hypertension, Systolic, Hypertension, Essential
Orchestra BioMed, Inc
Not applicable
316
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois
2023-12-27
Recruiting
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsNemtabrutinib·Ibrutinib·Acalabrutinib
Merck Sharp & Dohme LLC
Phase 3
1,200
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Indiana
2023-12-13
Active, closed
Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)
NCT06111586Type 1 Diabetes Mellitus
DrugFrexalimab
Sanofi
Phase 2
197
California, Colorado, Florida, Idaho, Illinois, Massachusetts, New York, North Carolina
2023-12-11
Recruiting
A Long-Term Follow-Up Study of Participants Exposed to REACT
NCT05918523Diabetic Kidney Disease, Chronic Kidney Diseases
Prokidney
Observational
80
Idaho
2023-12-11
Active, closed
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
NCT05976243Chronic Inducible Urticaria
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
362
Alabama, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2023-12-07
Active, closed
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760Non-small Cell Lung Cancer
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
868
Alaska, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2023-12-06
Active, closed
A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
NCT06101095Eosinophilic Oesophagitis
DrugDupilumab
Sanofi
Phase 4
69
California, Florida, Idaho, Illinois, Iowa, Massachusetts, Minnesota, North Carolina
2023-11-29
By invitation
Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen Product
NCT06790498Diabetic Kidney Disease, Chronic Kidney Disease
Prokidney
Observational
50
Idaho
2023-11-23
Recruiting
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
NCT06094010Influenza
DrugBaloxavir Marboxil
Hoffmann-La Roche
Phase 3
1,100
Alabama, Arkansas, Florida, Georgia, Idaho, Indiana, Kentucky, Louisiana
2023-11-22
Recruiting
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
NCT06143956Obesity, Overweight
DrugsMacupatide·Eloralintide·Mazdutide·Tirzepatide
Eli Lilly and Company
Phase 2
1,481
Arizona, California, Connecticut, Florida, Hawaii, Idaho, Illinois, Iowa
2023-11-17
Active, closed
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
NCT06063967Crohn's Disease
DrugsSkyrizi·Risankizumab
AbbVie
Phase 3
289
Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana
2023-11-15
Recruiting
Safety and Effectiveness of the Yaari Extractor for Management of Shoulder Dystocia
NCT05913609Shoulder Dystocia
FetalEase Ltd.
Not applicable
80
Florida, Idaho, North Carolina, Virginia
2023-11-15
Recruiting
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
NCT05977751Contraception
Femasys Inc.
Not applicable
573
Arizona, California, Georgia, Idaho, New York, Ohio, Tennessee, Utah
2023-10-31
Active, closed
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT06075667Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
160
Georgia, Idaho, Kansas, Louisiana, Maryland, Minnesota, Missouri, Ohio
2023-10-16
Active, closed
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
NCT06052267Asthma
Teva Branded Pharmaceutical Products R&D LLC
Phase 3
2,772
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2023-08-30
Active, closed
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
NCT05992935Norovirus Acute Gastroenteritis
DrugMRNA-1403
ModernaTX, Inc.
Phase 1/2
1,407
California, Colorado, Florida, Georgia, Idaho, Illinois, Iowa, Kansas
2023-08-25
Recruiting
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
NCT05862272Uterine Fibroids, Endometriosis
DrugMyfembree
Sumitomo Pharma Switzerland GmbH
Phase 3
1,000
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2023-08-14
Active, closed
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT05797610Primary IgA Nephropathy
Hoffmann-La Roche
Phase 3
459
Alabama, California, Florida, Georgia, Idaho, Illinois, Massachusetts, Nevada
2023-08-08
Active, closed
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
NCT05968430Hypertension
Mineralys Therapeutics Inc.
Phase 3
1,076
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2023-07-14
Active, closed
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
NCT05677451Chronic Spontaneous Urticaria
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
100
California, Florida, Idaho, Illinois, Kentucky, Ohio, Oklahoma, Pennsylvania
2023-07-11
Active, closed
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
NCT05726227Obesity
DrugSemaglutide
Novo Nordisk A/S
Phase 3
210
California, Connecticut, Georgia, Idaho, Louisiana, Maryland, Massachusetts, Minnesota
2023-07-07
Recruiting
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
NCT05504837Cystic Fibrosis
Krystal Biotech, Inc.
Phase 1
20
Florida, Idaho, Illinois, New York, North Carolina
2023-06-30
Active, closed
Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to a DMARD Starting a New bDMARD or tsDMARD Treatment +/- csDMARD
NCT05936970Rheumatoid Arthritis
Aqtual, Inc.
Observational
1,410
Arizona, California, Florida, Idaho, Illinois, Indiana, Michigan, Minnesota
2023-06-29
Active, closed
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
NCT05889182Hidradenitis Suppurativa
DrugUpadacitinib
AbbVie
Phase 3
1,328
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2023-06-21
Active, closed
Post-Market Registry in Europe and US for the Use of VascuCelTM
NCT04906824Great Vessel Reconstruction, Peripheral Vessel Reconstruction, Suture Line Buttressing
LeMaitre Vascular
Observational
100
Idaho, Nevada, New York, North Carolina
2023-06-09
Recruiting
Study of ALTO-300 in MDD
NCT05922878Major Depressive Disorder
Alto Neuroscience
Phase 2
321
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2023-06-08
Active, closed
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT05869903Obesity, Overweight, Overweight or Obesity
DrugOrforglipron
Eli Lilly and Company
Phase 3
3,127
Arizona, California, Colorado, Florida, Georgia, Hawaii, Idaho, Kansas
2023-06-05
Recruiting
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
NCT05716100Focal Onset Seizures
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
360
Arkansas, California, Florida, Idaho, Illinois, Maryland, Michigan, New Jersey
2023-05-09
By invitation
An Open-label Study of XEN1101 in Epilepsy
NCT05718817Focal Epilepsy, Tonic-Clonic Seizures
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
880
Arizona, Arkansas, California, Colorado, Florida, Hawaii, Idaho, Indiana
2023-04-25
Recruiting
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
NCT05775523Growth Hormone Deficiency
Ascendis Pharma Endocrinology Division A/S
Observational
500
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Indiana
2023-03-20
Recruiting
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
NCT05820672Growth Hormone Deficiency
Ascendis Pharma Endocrinology Division A/S
Observational
900
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Indiana
2023-03-20
Recruiting
A Study of BLB-201 RSV Vaccine in Infants and Children
NCT05655182Respiratory Syncytial Virus Infections
Blue Lake Biotechnology Inc.
Phase 1/2
137
California, Colorado, Georgia, Idaho, Kansas, Louisiana, Michigan, Nebraska
2023-03-09
By invitation
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05735483Atopic Dermatitis, Eczema
DrugLebrikizumab
Eli Lilly and Company
Phase 3
333
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Idaho, Illinois
2023-03-09
Active, closed
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
NCT05669755Cardiovascular Disease
DrugsCagrilintide·Semaglutide
Novo Nordisk A/S
Phase 3
7,101
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2023-03-01
Active, closed
A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome
NCT05690386Turner Syndrome
DrugSomatropin
Ascendis Pharma Endocrinology Division A/S
Phase 2
48
California, Colorado, Florida, Georgia, Idaho, Illinois, Massachusetts, Minnesota
2023-02-15
Active, closed
A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9
NCT05723835SGA, Turner Syndrome, Noonan Syndrome, ISS
DrugSomapacitan
Novo Nordisk A/S
Phase 3
47
Alabama, California, Colorado, District of Columbia, Idaho, Minnesota
2023-02-01
Active, closed
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
NCT05552976Relapsed or Refractory Multiple Myeloma
DrugsMezigdomide·Carfilzomib·Dexamethasone
Bristol-Myers Squibb
Phase 3
606
Alabama, California, Florida, Georgia, Idaho, Maryland, Massachusetts, Minnesota
2023-01-10
Recruiting
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450Viral Lung Infection and Acute Respiratory Failure
DrugTozorakimab
AstraZeneca
Phase 3
3,527
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2022-12-13
Active, closed
Dose Finding Study to Evaluate Safety and Efficacy of 3 Dosages of SAP 001.
NCT05690204Gout
DrugColchicine
Shanton Pharma Pte. Ltd.
Phase 2
87
California, Colorado, Florida, Idaho, Maryland, Mississippi, North Carolina, Texas
2022-12-12
Active, closed
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
NCT05444257Cystic Fibrosis
DrugVNZ/TEZ/D-IVA
Vertex Pharmaceuticals Incorporated
Phase 3
822
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2022-11-08
Active, closed
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
NCT05284747Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
DrugsRepatha·Evolocumab
Amgen
Phase 4
6,019
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois
2022-10-26
Active, closed
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05559359Atopic Dermatitis, Eczema
DrugLebrikizumab
Eli Lilly and Company
Phase 3
377
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Idaho, Illinois
2022-10-18
Active, closed
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
NCT05509023Atopic Dermatitis
DrugBempikibart
Q32 Bio Inc.
Phase 2
102
Alabama, California, Florida, Georgia, Idaho, Illinois, Indiana, Maryland
2022-09-30
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484Colitis, Ulcerative
DrugsJNJ-78934804·Golimumab·Guselkumab
Janssen Research & Development, LLC
Phase 2
577
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana
2022-09-19
Active, closed
Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine
NCT05516992Lumbar Degenerative Disc Disease
Spine BioPharma, Inc
Phase 3
417
Alabama, Arizona, California, Florida, Georgia, Idaho, Indiana, Kansas
2022-08-19
Active, closed
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
NCT05327530Locally Advanced or Metastatic Urothelial Carcinoma
DrugsAvelumab·Sacituzumab Govitecan
EMD Serono Research & Development Institute, Inc.
Phase 2
256
Idaho, Kansas, Maryland, Missouri, Washington, Wisconsin
2022-08-17
Active, closed
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
NCT05330325SGA, Turner Syndrome, Noonan Syndrome, ISS
DrugsNorditropin·Somapacitan
Novo Nordisk A/S
Phase 3
412
Alabama, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Idaho
2022-08-10
Active, closed
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 3
586
Alaska, Arkansas, California, Florida, Georgia, Idaho, Maryland, Massachusetts
2022-07-08
Recruiting
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
NCT05354141Acute Respiratory Distress Syndrome, ARDS
Direct Biologics, LLC
Phase 3
970
Arizona, Arkansas, California, District of Columbia, Florida, Idaho, Iowa, Maryland
2022-07-01
Active, closed
HEAL-IST IDE Trial
NCT05280093Inappropriate Sinus Tachycardia
AtriCure, Inc.
Not applicable
142
Arkansas, California, Connecticut, District of Columbia, Florida, Georgia, Idaho, Kansas
2022-05-31
Recruiting
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646FSGS
DrugRepagermanium
Dimerix Bioscience Pty Ltd
Phase 3
286
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2022-05-30
Recruiting
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
NCT05219617Seizures, Lennox Gastaut Syndrome
SK Life Science, Inc.
Phase 3
252
California, Florida, Idaho, Kentucky, Louisiana, Maryland, Minnesota, Missouri
2022-04-28
Active, closed
INTIBIA Pivotal Study
NCT05250908Urinary Incontinence, Urge, Urinary Bladder, Overactive, Urinary Bladder Diseases, Urologic Diseases
Coloplast A/S
Not applicable
208
California, District of Columbia, Florida, Georgia, Idaho, Kansas, Massachusetts, Michigan
2022-03-07
Active, closed
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
NCT05090371Relapsing-Remitting Multiple Sclerosis
DrugOfatumumab
Novartis Pharmaceuticals
Phase 4
136
Alabama, Arizona, California, Florida, Idaho, Louisiana, Maryland, Massachusetts
2022-03-02
Recruiting
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
NCT05156398Migraine
DrugRimegepant
Pfizer
Phase 3
640
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois
2022-02-28
By invitation
A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
NCT05076617Stereotypical Prolonged Seizures
DrugStaccato alprazolam
UCB Biopharma SRL
Phase 3
300
Arizona, Arkansas, California, District of Columbia, Florida, Hawaii, Idaho, Illinois
2022-02-03
Active, closed
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
NCT05099770Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Prokidney
Phase 3
685
Alabama, Arizona, California, Delaware, Florida, Georgia, Idaho, Illinois
2022-01-05
Active, closed
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
NCT05164094Epstein-Barr Virus Infection
DrugMRNA-1189
ModernaTX, Inc.
Phase 1/2
867
Alabama, California, Florida, Georgia, Idaho, Illinois, Indiana, Iowa
2021-12-28
Active, closed
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
NCT04999969Locally Advanced or Metastatic Solid Tumours
DrugsAZD0171·Durvalumab·Nab-paclitaxel·Gemcitabine
AstraZeneca
Phase 2
126
California, Georgia, Idaho, Massachusetts, Michigan, New York, Oregon, Texas
2021-12-10
Recruiting
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
NCT05077904Stereotypical Prolonged Seizures
DrugStaccato alprazolam
UCB Biopharma SRL
Phase 3
350
Arizona, Arkansas, California, Connecticut, District of Columbia, Florida, Hawaii, Idaho
2021-12-07
Active, closed
Desara ® One Single Incision Sling 522 Study
NCT04772131Stress Urinary Incontinence
Caldera Medical, Inc.
Not applicable
300
Arizona, Florida, Idaho, Indiana, Kentucky, Massachusetts, Missouri, Nevada
2021-11-01
By invitation
Multi-Center Clinical Database of Infants for the Investigation of Early Nutrition Biomarkers
NCT05049655Infant Development
ByHeart
Observational
2,000
Alabama, Arizona, Arkansas, Idaho, Ohio, South Carolina, Tennessee, Utah
2021-10-19
By invitation
SPI-1005 Treatment in Moderate COVID-19 Patients
NCT04484025Covid19, Corona Virus Infection, Coronavirus, Coronavirus Infection
DrugEbselen
Sound Pharmaceuticals, Incorporated
Phase 2
60
Connecticut, Idaho, Kansas, Missouri, North Carolina, Texas
2021-10-12
Recruiting
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
NCT04889872Aortic Stenosis, Calcific, Aortic Valve Stenosis
Edwards Lifesciences
Not applicable
2,250
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2021-10-12
Recruiting
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
NCT04557462Primary IgA Nephropathy
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
540
Arizona, California, Colorado, Delaware, Idaho, Illinois, Maryland, Massachusetts
2021-09-20
Active, closed
Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.
NCT05035212Lower Respiratory Tract Illness
DrugRSVpreF
Pfizer
Phase 3
38,861
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2021-08-31
Active, closed
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866Alzheimer Disease
DrugDonanemab
Eli Lilly and Company
Phase 3
2,996
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2021-08-27
Active, closed
Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.
NCT05024695Glaucoma
iSTAR Medical
Not applicable
975
Arizona, Arkansas, California, Colorado, Florida, Idaho, Illinois, Kansas
2021-08-19
Active, closed
Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
NCT04959448Chronic Rhinosinusitis With Nasal Polyposis
DrugDupilumab
Regeneron Pharmaceuticals
Observational
717
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2021-08-12
Active, closed
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
NCT04960709Muscle Invasive Bladder Cancer
DrugsEnfortumab Vedotin·Tremelimumab·Durvalumab
AstraZeneca
Phase 3
712
California, Connecticut, District of Columbia, Florida, Idaho, Illinois, Indiana, Iowa
2021-08-05
By invitation
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
NCT04976322Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
760
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2021-07-27
Active, closed
M6-C Artificial Cervical Disc Two-Level IDE Pivotal Study
NCT04982835Cervical Disc Degenerative Disorder
Orthofix Inc.
Not applicable
156
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Massachusetts
2021-07-26
Active, closed
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
NCT04908202Psoriatic Arthritis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
670
Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2021-07-13
Active, closed
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
NCT04877691Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
367
Alabama, Arizona, California, Colorado, Florida, Idaho, Michigan, New Jersey
2021-06-08
Active, closed
Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
NCT06596252Eosinophilic Esophagitis
DrugBudesonide
Dr. Falk Pharma GmbH
Phase 3
308
Arizona, Arkansas, California, Florida, Idaho, Massachusetts, Michigan, Minnesota
2021-05-21
Active, closed
Eversense® Non-adjunctive Use Post Approval Study
NCT04836546Diabetes
Senseonics, Inc.
Not applicable
925
California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Louisiana
2021-04-13
Active, closed
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
NCT04775082Obesity
DrugLiraglutide
Novo Nordisk A/S
Phase 3
78
Arizona, Colorado, Idaho, Louisiana, Maryland, Minnesota, New York, Ohio
2021-03-04
Active, closed
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT04589845Solid Tumors
DrugsCamonsertib·Belvarafenib·Pralsetinib·Divarasib
Hoffmann-La Roche
Phase 2
920
Arizona, California, Georgia, Idaho, Illinois, Indiana, Maryland, Michigan
2021-01-18
Active, closed
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
NCT04616326Chronic Migraine
DrugGalcanezumab
Eli Lilly and Company
Phase 3
312
Alabama, Arizona, California, Colorado, Florida, Idaho, Illinois, Kansas
2020-11-25
Active, closed
Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
NCT04636697SARS-CoV-2 Infection
Medicago
Phase 2/3
30,918
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Idaho, Illinois
2020-11-19
Active, closed
Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)
NCT04598893Diabetes Mellitus, Type 1
DrugTeplizumab
Provention Bio, a Sanofi Company
Observational
188
California, Colorado, Florida, Georgia, Idaho, Indiana, Iowa, Maryland
2020-10-26
Recruiting
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
NCT04427384Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic
GT Medical Technologies, Inc.
Observational
600
Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho, Indiana
2020-09-11
Active, closed
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
NCT04401748Myelodysplastic Syndrome (MDS)
DrugsVenclexta·Azacitidine·Venetoclax
AbbVie
Phase 3
531
California, Colorado, Connecticut, Delaware, Florida, Idaho, Illinois, Indiana
2020-09-10
Active, closed
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
NCT04232553Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
996
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Indiana
2020-06-22
Active, closed
Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
NCT04199689Papillomavirus Infections
DrugNonavalent HPV vaccine
Merck Sharp & Dohme LLC
Phase 3
6,033
California, Florida, Georgia, Idaho, Kansas, Kentucky, Missouri, Nevada
2020-02-27
Active, closed
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
NCT03937154Chemotherapy-induced Thrombocytopenia
DrugsNplate·Romiplostim
Amgen
Phase 3
145
Arkansas, California, Colorado, Florida, Idaho, Illinois, Louisiana, Maryland
2020-02-26
Recruiting
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
NCT05986292Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
Eli Lilly and Company
Phase 2
10,000
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2020-01-30
Active, closed
A 5-year Superion™ IDS Clinical Outcomes Post-Approval Evaluation (SCOPE)
NCT04192591Lumbar Spinal Stenosis
Boston Scientific Corporation
Not applicable
166
California, Florida, Georgia, Idaho, Illinois, Kansas, Massachusetts, Michigan
2020-01-30
Active, closed
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
NCT03989206Moderate-to-Severe Atopic Dermatitis
DrugNemolizumab
Galderma R&D
Phase 3
1,700
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2019-12-30
By invitation
MDR - Comprehensive Primary/Micro Stem & Versa-Dial Ti Humeral Head
NCT04003311Shoulder Pain, Shoulder Injuries, Shoulder Fractures, Shoulder Disease
Zimmer Biomet
Observational
146
Idaho, Michigan, New York, Vermont
2019-12-13
Active, closed
Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry
NCT04076813Myocardial Infarction
Chiesi USA, Inc.
Observational
5,050
California, Delaware, Florida, Idaho, Maryland, Massachusetts, Michigan, Missouri
2019-10-16
Recruiting
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
NCT03887715Treatment Resistant Depression
LivaNova
Not applicable
6,800
Alabama, California, Florida, Georgia, Idaho, Illinois, Indiana, Kansas
2019-09-26
Active, closed
A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day
NCT03878446Short Stature Children Born Small for Gestational Age (SGA)
DrugsNorditropin·Somapacitan
Novo Nordisk A/S
Phase 2
62
Alabama, California, Idaho, Minnesota, New Jersey, New York, Ohio, Oklahoma
2019-07-04
Active, closed
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
NCT03898479Alopecia Areata
Sun Pharmaceutical Industries, Inc.
Phase 2/3
1,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Idaho
2019-04-04
Recruiting
Deep Brain Stimulation (DBS) Retrospective Outcomes Study
NCT03664609Parkinson Disease, Essential Tremor, Dystonia
Boston Scientific Corporation
Observational
5,000
Arizona, California, Florida, Idaho, New York, North Carolina, Pennsylvania, Washington
2019-03-12
Active, closed
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
NCT03765918Head and Neck Neoplasms
DrugsKeytruda·Cisplatin·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
714
California, Colorado, District of Columbia, Florida, Idaho, Illinois, Kansas, Kentucky
2018-12-17
Active, closed
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
NCT03762850Immunoglobulin A Nephropathy
DrugsSparsentan·Irbesartan·Dapagliflozin
Travere Therapeutics, Inc.
Phase 3
406
Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2018-12-11
Active, closed
Evaluation of Efficacy, Safety and Tolerability of VeraCept IUS
NCT03633799Women at Risk for Pregnancy
Sebela Women's Health Inc.
Phase 3
1,620
Arizona, California, Colorado, Florida, Georgia, Idaho, Indiana, Louisiana
2018-08-22
Active, closed
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03568318Atopic Dermatitis
DrugUpadacitinib
AbbVie
Phase 3
1,533
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois
2018-08-09
Active, closed
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945Ulcerative Colitis
DrugMirikizumab
Eli Lilly and Company
Phase 3
1,058
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2018-07-18
Active, closed
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
NCT03433274Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases
Abbott Medical Devices
Not applicable
103
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2018-06-15
Active, closed
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
NCT03345823Crohn's Disease
DrugUpadacitinib
AbbVie
Phase 3
747
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2018-03-21
Active, closed
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
NCT03432286Episodic Migraine
DrugGalcanezumab
Eli Lilly and Company
Phase 3
533
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2018-03-14
Active, closed
LEADERS FREE II: BioFreedom™ Pivotal Study
NCT02843633Acute Coronary Syndrome, High Bleeding Risk
Biosensors Europe SA
Not applicable
1,203
Alabama, Arkansas, California, District of Columbia, Florida, Georgia, Idaho, Illinois
2017-02-14
Active, closed
McNeel Eye Center Corneal Crosslinking Study
NCT02921009Keratoconus
McNeel Eye Center
Not applicable
100
Idaho
2016-09-01
Recruiting
RHythmia mAPping and Signal acquisitiOn for Data analYsis (RHAPSODY)
NCT03053141Cardiac Arrythmias
Boston Scientific Corporation
Observational
100
Alabama, Idaho, Massachusetts, New Hampshire, New Jersey
2016-05
Active, closed
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
NCT02629159Rheumatoid Arthritis
DrugsHumira·Adalimumab·Upadacitinib
AbbVie
Phase 3
1,629
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2015-12-01
Active, closed
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
NCT02531516Prostatic Neoplasms
DrugsGnRH·Bicalutamide·Apalutamide
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois
2015-11-19
Recruiting
Specimen Collection From Patients With Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay
NCT02586389Non-hematologic Cancer
Sequenom, Inc.
Observational
3,000
Idaho
2015-10-13
Recruiting
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
NCT02071134Parkinson's Disease
Boston Scientific Corporation
Observational
1,500
California, Colorado, Florida, Idaho, Illinois, Indiana, Massachusetts, Missouri
2014-03-04
Active, closed
NOVOCART®3D for Treatment of Articular Cartilage of the Knee
NCT01957722Articular Cartilage of the Femoral Condyle Between 2-6cm2
DrugNOVOCART 3D
Aesculap Biologics, LLC
Phase 3
233
California, Colorado, Florida, Idaho, Illinois, Kentucky, Louisiana, Michigan
2013-12
Active, closed
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
NCT01946204Prostatic Neoplasms
DrugApalutamide
Aragon Pharmaceuticals, Inc.
Phase 3
1,207
Alabama, Alaska, Arizona, California, Colorado, District of Columbia, Florida, Idaho
2013-10-14
Recruiting
Patient Retrospective Outcomes (PRO)
NCT01550575Chronic Pain
Boston Scientific Corporation
Observational
15,000
Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Idaho
2012-04-03
Active, closed
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
NCT00781612Neoplasm Metastasis
DrugsPerjeta·Ado-trastuzumab emtansine·Trastuzumab emtansine·Herceptin
Genentech, Inc.
Phase 2
378
California, Colorado, Delaware, Florida, Georgia, Idaho, Illinois, Indiana
2008-10-16
Active, closed
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
NCT00606346Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, Inflammatory Bowel Diseases
Janssen Biotech, Inc.
Observational
4,970
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2007-05-31
Rows per page Showing 1–329 of 329
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/state/idaho

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 329 of those studies with a site in Idaho.

How many clinical trials are recruiting in Idaho?

164 of the 329 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 6 have not yet opened recruitment, 147 are active but closed to new participants, and 12 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Idaho), 329 studies
PhaseStudiesRecruitingShare
Phase 31849655.9%
Phase 2673220.4%
Not applicable29138.8%
Observational25157.6%
Phase 2/3832.4%
Phase 4812.4%
Phase 1/2521.5%
Phase 1320.9%

Most active sponsors

Lead sponsors with the most studies (Idaho)
Lead sponsorStudiesRecruiting
Eli Lilly and Company3316
AbbVie157
AstraZeneca1510
Novo Nordisk A/S145
Pfizer1412
Boston Scientific Corporation96
Merck Sharp & Dohme LLC96
Sanofi93
Amgen85
Hoffmann-La Roche85
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.